Grifols (GRFS) Cost of Revenue (2010 - 2020)
Grifols (GRFS) posted Cost of Revenue of $775.1 million for Q1 2020, down 65.08% quarter-over-quarter from $2.2 billion in Q4 2019, and up 8.46% year-on-year from $714.6 million in Q2 2019.
Grifols (GRFS) Cost of Revenue (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Cost of Revenue for 10 consecutive years, with $775.1 million the latest figure, recorded in Q1 2020.
- Cost of Revenue for Q1 2020 came in at $775.1 million, up 8.46% year-over-year; the trailing twelve-month figure through Mar 2020 was $5.7 billion (up 40.75% YoY), and the FY2025 annual result was $5.4 billion, up 15.02% from the prior year.
- Cost of Revenue was $775.1 million for Q1 2020 at Grifols, down from $2.2 billion in the prior quarter.
- Over five years, Cost of Revenue peaked at $2.2 billion in Q4 2019 and troughed at $553.8 million in Q1 2017.
- Average Cost of Revenue over 5 years is $995.6 million, with a median of $674.0 million recorded in 2018.
- Year-over-year, Cost of Revenue increased 3.94% in 2016 and jumped 195.8% in 2017.
- Over 5 years, Cost of Revenue stood at $643.1 million in 2016, then jumped by 195.8% to $1.9 billion in 2017, then increased by 3.94% to $2.0 billion in 2018, then climbed by 12.25% to $2.2 billion in 2019, then plunged by 65.08% to $775.1 million in 2020.
- Per Business Quant data, the three most recent Cost of Revenue figures were $775.1 million in Q1 2020, $2.2 billion in Q4 2019, and $714.6 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 8.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.22 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 2.68 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 775.06 Mn |
| Mar 31, 2020 | 775.06 Mn |
| Dec 31, 2019 | 2.22 Bn |
| Dec 31, 2019 | 2.22 Bn |
| Mar 31, 2019 | 714.63 Mn |
| Mar 31, 2019 | 714.63 Mn |
| Dec 31, 2018 | 1.98 Bn |
| Dec 31, 2018 | 1.98 Bn |
| Jun 30, 2018 | 691.82 Mn |
| Jun 30, 2018 | 691.82 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Dec 31, 2017 | 1.90 Bn |
| Dec 31, 2017 | 1.90 Bn |
| Jun 30, 2017 | 626.15 Mn |
| Jun 30, 2017 | 626.15 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Dec 31, 2016 | 643.10 Mn |
| Dec 31, 2016 | 643.10 Mn |